Artesunate for Injection Now Available for Severe Malaria
Artesunate and its metabolite DHA are both active against the blood-stage asexual parasites and gametocytes of Plasmodium species including the chloroquine resistant strains.
Artesunate and its metabolite DHA are both active against the blood-stage asexual parasites and gametocytes of Plasmodium species including the chloroquine resistant strains.
The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.
The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
This slideshow shows drug information for Arakoda. Click here for the complete Arakoda monograph.
Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.
When writing a prescription for a patient, it’s important to review the patient’s prior medical history – particularly when it is a patient who doesn’t come in regularly.
The approval of Arakoda was based on over 21 trials involving over 3100 patients.
In clinical trials, tafenoquine, an 8-aminoquinoline, demonstrated efficacy against 2 primary types of malaria, Plasmodium vivax and P. falciparum malaria.
The approval was based on data from 3 randomized, double-blind studies, DETECTIVE Part 1 and Part 2 and GATHER.
To assess safety and efficacy of artemisinin-based combination therapies (ACTs) during pregnancy, researchers from the CDC conducted an analysis of the literature which included clinical trials, observational studies, meta-analyses and case reports conducted in Asia and Africa.